EDSA: Positive exploratory data in patients with AKI
- Posted on July 2, 2026
- By Bing News
- 0 Views
- 1 min read
EDSA: Positive exploratory data in patients with AKI
By David Bautz, PhD NASDAQ: EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Positive Exploratory Data for Paridiprubart in AKI In June 2026, Edesa Biotech, Inc. (NASDAQ: EDSA) announced the presentation of positive exploratory data for paridiprubart (EB05), the company’s first-in-class anti-TLR4 monoclonal antibody, in patients with acute kidney injury (AKI) and acute respiratory distress syndrome (ARDS). The data expanded on previously...
